Biogen (BIIB) said Wednesday that the US Food and Drug Administration has granted fast track designation to its investigational antisense oligonucleotide therapy BIIB080 aimed at treating Alzheimer's disease.
The company said BIIB080 is the first tau-targeting ASO therapy to enter clinical development for Alzheimer's and is currently being evaluated in a global phase 2 study in individuals with early-stage disease.
Biogen said the phase 2 trial is fully enrolled and a data readout is expected in 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.